GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide 
drug based on telomerase modification has released further positive data at the 
Korean Dementia Association's Fall Conference from a Phase II trial in 
Alzheimer's disease of lead candidate GV1001. Previously the company announced 
GV1001 was well tolerated and safe and the primary endpoint was achieved with 
notable improvements in Severe Impairment Battery (SIB) scores. The newly 
released data also shows a statistically significant improvement in the 
Neuropsychiatric Inventory (NPI) and an improvement trend in Alzheimer's 
Disease Cooperative Study-Activities of Daily living (ADCS-ADL). Based on these 
results, the company is now planning to submit a Phase III IND application.

GemVax's GV1001 Phase II clinical trial evaluated the safety and efficacy of 
subcutaneous injection of GV1001 0.56 mg or 1.12 mg for six months in patients 
with moderate-to-severe Alzheimer's disease already receiving donepezil for 
more than three months, at 12 medical institutions. PI Professor Seong-Ho Koh, 
at Hanyang University Guri Hospital  said, "The Severe Impairment Battery 
(SIB), the primary endpoint of this clinical study, showed an statistically 
significant greater improvement in the group treated with GV1001 1.12 mg 
compared with the control group treated with donepezil alone, which showed 7.11 
difference in the overall SIB score. Among the secondary outcome results, the 
group treated with GV1001 1,12mg had a significant greater improvement in the 
Neuropsychiatry Inventory (NPI) scores compared to the control group. 
Furthermore, although found to be statistically not significant, the other 
secondary outcome, the Alzheimer's disease cooperative study, Activities of 
Daily living (ADCS-ADL) score showed an apparent trend in improvement similar 
to the SIB results."

Kim Sang-Jae, chairman of GemVax "Combined with the notable improvement in SIB 
scores in patients with moderate-to-severe Alzheimer's disease, these 
significant results in NPI and ADCS-ADL scores are extremely encouraging. We 
have decided to submit a Phase III in Korea to see if it is possible to 
demonstrate improvement in a larger group of  moderate-to-severe patients."
Professor Koh, agrees, "If efficacy and safety results of GV1001 in the phase 
III clinical trial are the same as or superior to the Phase II clinical trial, 
it will be able to establish itself as a game-changer in Alzheimer's disease 
treatment". 

For more information visit: www.gemvax.com

Media Contact 
Richard Hayhurst 
T: +44-7711-821-527
E: Richard@rhapr.eu  

SOURCE: GemVax & KAEL